Literature DB >> 11192901

Recurrent respiratory papillomatosis.

C S Derkay1.   

Abstract

Recurrent respiratory papillomatosis (RRP) is the most common benign neoplasm of the larynx in children. Despite its benign histology, RRP has potentially morbid consequences and is often difficult to treat because of its tendency to recur and spread throughout the respiratory tract. Long neglected from an epidemiological standpoint, recent initiatives to better understand this disease process have been launched through coordination between the Centers for Disease Control and Prevention and the American Society of Pediatric Otolaryngology. In this clinical review, I discuss what we currently know regarding the etiology, epidemiology, and transmission of this disease. Clinical features including pertinent aspects of the history, physical examination, airway endoscopy, and other considerations are highlighted. A detailed description of the surgical and anesthetic management of these challenging cases is presented. Adjuvant modalities of surgical and nonsurgical treatment and their indications are discussed. Ongoing research initiatives and the Practice Guidelines of the Recurrent Respiratory Papillomatosis Task Force are also included.

Entities:  

Mesh:

Year:  2001        PMID: 11192901     DOI: 10.1097/00005537-200101000-00011

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  26 in total

1.  Treatment of recurrent respiratory papillomatosis with microsurgery in combination with intralesional cidofovir--a prospective study.

Authors:  Frederik G Dikkers
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-11-22       Impact factor: 2.503

2.  Intralesional Cidofovir application in recurrent laryngeal papillomatosis.

Authors:  Annett Pudszuhn; Cornelia Welzel; Marc Bloching; Kerstin Neumann
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-10-13       Impact factor: 2.503

Review 3.  [Current therapeutic options for recurrent respiratory papillomatosis].

Authors:  K Huber; H Sadick; K Götte
Journal:  HNO       Date:  2005-11       Impact factor: 1.284

Review 4.  Adjuvant antiviral therapy for recurrent respiratory papillomatosis.

Authors:  Neil K Chadha; Adrian James
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

5.  Recurrent respiratory papillomatosis causing chronic stridor and delayed speech in an 18-month-old boy.

Authors:  Adel Alharbi; Derek Drummond; Alfredo Pinto; Valerie Kirk
Journal:  Can Respir J       Date:  2006-10       Impact factor: 2.409

6.  Increased expression of the prolactin receptor is associated with malignant laryngeal tumors.

Authors:  Luis R González-Lucano; José F Muñoz-Valle; Rafael Ascencio-Cedillo; José A Domínguez-Rosales; Gonzalo López-Rincón; Susana Del Toro-Arreola; Miriam Bueno-Topete; Adrián Daneri-Navarro; Ciro Estrada-Chávez; Ana L Pereira-Suárez
Journal:  Exp Ther Med       Date:  2012-01-30       Impact factor: 2.447

7.  Analysis of CD4(+) T-cell responses to human papillomavirus (HPV) type 11 L1 in healthy adults reveals a high degree of responsiveness and cross-reactivity with other HPV types.

Authors:  O Martin Williams; Keith W Hart; Eddie C Y Wang; Colin M Gelder
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

8.  Multicenter initiative seeking critical genes in respiratory papillomatosis.

Authors:  Farrel J Buchinsky; Craig S Derkay; Suzanne M Leal; Joseph Donfack; Garth D Ehrlich; J Christopher Post
Journal:  Laryngoscope       Date:  2004-02       Impact factor: 3.325

Review 9.  [Laryngeal papillomatosis: etiology, diagnostics and therapy].

Authors:  M Andratschke; C Betz; A Leunig
Journal:  HNO       Date:  2008-12       Impact factor: 1.284

10.  Sensitive HPV detection in oropharyngeal cancers.

Authors:  David M Winder; Siolian L R Ball; Katie Vaughan; Nashat Hanna; Yin Ling Woo; Jürgen-Theodor Fränzer; Jane C Sterling; Margaret A Stanley; Holger Sudhoff; Peter K C Goon
Journal:  BMC Cancer       Date:  2009-12-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.